
|Articles|July 1, 2004
Dorzolomide HCI OK for use in children
The FDA has approved Merck Human Health's dorzolomide HCI (Trusopt) ophthalmic solution 2% for use in pediatric patients. The drug is used to treat elevated IOP in patients with ocular hypertension or open-angle glaucoma.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Study identifies 6 key genes linking air pollution to dry eye disease
2
4DMT releases positive interim 1.5- to 3.5-year data from phase 1/2 PRISM trial
3
Q&A: Karolinne M. Rocha discusses the IOL and patient tolerance of residual astigmatism
4
Avisi Technologies releases positive 12-month data from VITA Trial
5


















































.png)


